Aurora Cannabis Inc. logo

Aurora Cannabis Inc.

ACB

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Previous close

$3.94

+$0.13 · +3.41%

Aug 21, 4:00 PM ET

ACB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

21

Weakening

Sentiment

46

Mixed

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CA
CEO
Miguel Martin
Listed since
Jul 15, 2014
Employees
1,028

Market position

Day range

Current $3.94

52-week range

Current $3.94

Open
$3.825
Previous close
$3.81
Volume
1.37M
1.01× average
Average volume
1.36M
Average daily volume
Market cap
244.05M USD
Beta
1.34
Market reference 1
50-day average
$2.9653
+32.87% above average
200-day average
$3.6601
+7.65% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
169.2M CAD
P/E (TTM)
-2.81×
P/B (TTM)
0.64×
P/S (TTM)
1.16×
EV / EBITDA
-3.32×
Earnings yield
-47.18%
Free cash flow yield
-13.97%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
32.08%
Operating margin
-29.66%
Net margin
-38.15%
Return on equity
-23.73%
Return on assets
-20.20%
Return on invested capital
-8.62%

Financial health

Debt / equity
0.04×
Current ratio
5.94×
Altman Z-score
-11.67
Piotroski F-score
2 of 9

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
+713.92%
11 comparable reports
Latest EPS result
-0.05
Estimate -0.13 · Beat by 64.60%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.480.06-0.37-0.8Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 0.396, estimate 0.003, surprise +11688.69%, Beat. Q2 2025, reported Jun 18, 2025: actual -0.243, estimate 0.11, surprise -321.08%, Miss. Q3 2025, reported Aug 6, 2025: actual -0.19, estimate 0.18, surprise -205.56%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.652, estimate 0.03, surprise -2274.83%, Miss. Q1 2026, reported Feb 4, 2026: actual 0.023, estimate 0.097, surprise -75.95%, Miss. Q2 2026, reported Jun 11, 2026: actual -0.71, estimate -0.07, surprise -914.14%, Miss. Q3 2026, reported Aug 5, 2026: actual -0.046, estimate -0.13, surprise +64.60%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates74.88M64.78M54.67M44.57MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 61.29M USD, estimate 55.5M USD, surprise +10.43%, Beat. Q2 2025, reported Jun 18, 2025: actual 62.91M USD, estimate 61.72M USD, surprise +1.93%, Beat. Q3 2025, reported Aug 6, 2025: actual 72M USD, estimate 70.76M USD, surprise +1.75%, Beat. Q4 2025, reported Nov 5, 2025: actual 64.88M USD, estimate 62.05M USD, surprise +4.57%, Beat. Q1 2026, reported Feb 4, 2026: actual 68.59M USD, estimate 67.26M USD, surprise +1.97%, Beat. Q2 2026, reported Jun 11, 2026: actual 60.98M USD, estimate 54.42M USD, surprise +12.05%, Beat. Q3 2026, reported Aug 5, 2026: actual 47.56M USD, estimate 47.45M USD, surprise +0.23%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 52.32M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

14 ratings
Strong buy00%
Buy321%
Hold857%
Sell321%
Strong sell00%

Corporate actions

Corporate action history

Stock split

Effective Feb 20, 2024

1:10

Stock split

Effective May 11, 2020

1:12

ACB peers

ETFs holding ACB

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ACB

research.disclaimer